Dengue vaccine development: Strategies and challenges

Viral Immunology

Volumn 28, Issue 2, 2015, Pages 76-84

  Ramakrishnan, Lakshmy ^a,b   Pillai, Madhavan Radhakrishna ^a   Nair, Radhakrishnan R ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

^b MANIPAL SCHOOL OF LIFE SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; DENGUE VACCINE; DNA VACCINE; INACTIVATED VIRUS VACCINE; LARVICIDAL AGENT; LIVE VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; BIOLOGICAL PEST CONTROL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE STORM; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL MANAGEMENT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION CONTROL; INFECTION RISK; INFECTION SENSITIVITY; INNATE IMMUNITY; MUTAGENESIS; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; SECONDARY INFECTION; SEROTYPE; VACCINATION; VECTOR CONTROL; VIRUS INFECTIVITY; VIRUS INTERFERENCE; VIRUS REPLICATION; DENGUE VIRUS; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; TRENDS;

DENGUE VIRUS;

DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG DISCOVERY; HUMANS;

EID: 84923101832     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2014.0093     Document Type: Review

References (99)

1. Aihara H, Takasaki T, Toyosaki-Maeda T, et al. T-cell activation and induction of antibodies and memory T cells by immunisation with inactivated Japanese encephalitis vaccine. Viral Immunol 2000;13:179-186.
2. Alcaraz-Estrada SL, Yocupicio-Monroy M, and del Angel RM. Insights into dengue virus replication. Future Virol 2010;5:575-592.
3. Alen MMF, and Schols D. Dengue virus entry as target for antiviral therapy. J Trop Med 2012;2012:1-13.
4. Amarasinghe A, Wichmann O, Margolis HS, et al. Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum Vaccines 2010;6:745-753.
5. Anderson KB, Gibbons RV, Edelman R, et al. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 2011;204:442-450.
6. Bangham CRM, Cannon MJ, Karzon DT, et al. Cytotoxic T cell response to respiratory syncytial virus in mice. J Virol 1985;56:55-59.
7. Betancourt-Cravioto M, Kuri-Morales P, Gonzalez-Roldan JF, et al. Introducing a dengue vaccine to Mexico: development of a system for evidence-based public policy recommendations. PLoS Negl Trop Dis 2014;8:e3009.
8. Bhamarapravati N, and Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000;18:44-47.
9. Bian G, Xu Y, Lu P, et al. The endosymbiotic bacterium Wolbachia induces resistance to dengue virus in Aedes aegypti. PLoS Pathog 2010;6:e1000833.
10. Blok J. Genetic relationships of the dengue virus serotypes. J Gen Virol 1985;66:1323-1325.
11. Bray M, and Geisbet TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola haemorrhagic fever. Int J Biochem Cell Biol 2005;8:1560-1568.
12. Cann AJ. Pathogenesis. In: Principles of Molecular Virology. 5th ed. San Diego, CA: Elsevier Academic Press, 2005:208-248.
13. Capeding MR, Tran NH, Hadinegoro DR, et al. Clinical Efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014;384:1358-1365.
14. Chang MS, Christophel EM, Gopinath D, et al. Challenges and future perspective for dengue vector control in the Western Pacific Region. Western Pac Surveill Response J 2011;2:9-16.
15. + T cell polarisation by dengue virus-infected dendritic cells. J Infect Dis 2011;203:1763-1774.
16. Chen MC, Lin CF, Lei HY, et al. Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. J Virol 2009;183:1797-1803.
17. Chen Y, Maguire T, and Marks RM. Demonstration of binding of dengue virus envelope protein to target cells. J Virol 1996;70:8765-8772.
18. Chuansumrit A, and Tangnararatchakit K. Pathophysiology and management of dengue haemorrhagic fever. Transfus Altern Transfus Med 2006;8:3-11.
19. Clements DE, Coller BA, Lieberman MM, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010;28:2705-2715.
20. Cohen P. Immunity's yin and yang. International AIDS Vaccine Report 2006;10.
21. Coller BG, Clements DE, Bett AJ, et al. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011;29:7267-7275.
22. Costa SM, Freire MS, and Alves AMB. DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. Vaccine 2006;24:4562-4564.
23. Daffis S, Samuel MA, Suthar MS, et al. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 2008;82:10349-10358.
24. Dengue Vaccine Initiative: Dengue Prevention Boards 2014. Available at www.denguevaccine.org/consortium (accessed October 1, 2014).
25. de St Groth SF, and Webster RG. Disquisitions on original antigenic sin. I Evidence in man. J Exp Med 1966;124:331-345.
26. Douglas DL, DeRoeck DA, Mahoney RT, et al. Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders. PLoS Negl Trop Dis 2013;7:e2127.
27. Durbin AP, Whitehead SS, Shaffer D, et al. A single dose of the DENV-1 candidate vaccine rDEN1D30 is strongly immunogenic and induces resistance to a second dose in a randomised trial. PLoS Negl Trop Dis 2011;5:1-10.
28. Edelman R. Unique challenges faced by the clinical evaluation of dengue vaccines. ExpRev Vaccines 2011;10:133-136.
29. Ekiert DC, and Wilson IA. Broadly neutralising antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol 2012;2:134-141.
30. Fernandez S. Immunogenicity and protection elicited by adjuvanted tetravalent dengue virus purified inactivated vaccine (TDENV PIV) in rhesus macaques. ASTMH 61st Annual Meeting, November 11-15, 2012, Atlanta, GA.
31. Franz AWE, Sanchez-Vargas I, Adelman ZN, et al. Engineering RNA interference-based resistance to dengue virus type 2 in genetically modified Aedes aegypti. Proc Natl Acad Sci U S A 2006;103:4198-4203.
32. Frentiu FD, Zakir T, Walker T, et al. Limited dengue virus replication in field-collected Aedes aegypti mosquitoes infected with Wolbachia. PLoS Negl Trop Dis 2013;8:e2688.
33. Griffin DE. Emergence and re-emergence of viral diseases of the central nervous system. Prog Neurobiol 2010;91:95-101.
34. st century. Trop Med Health 2011;39:3-11.
35. st century. Dengue Bull 1997;21:1-19.
36. Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010;8:632-649.
37. Guy B, Saville M, and Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010;6:696-705.
38. Guy B. Immunogenicity of Sanofi Pasteur tetravalent dengue vaccine. J Clin Virol 2009;46:S16-S19.
39. Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nature Rev Microbiol 2010;8:7-16.
40. Hall JE. The body fluids and kidneys. In: Guyton and Hall Textbook of Medical Physiology. 12th ed. Philadelphia, PA: Saunders, 2011:285-300.
41. Halstead SB, and Marchette NJ. Biologic properties of dengue viruses following serial passage in primary dog kidney lines: studies at the University of Hawaii. Am J Trop Med Hyg 2003;69:5-11.
42. Halstead SB. Observations related to pathogenesis of dengue haemorrhagic fever. Yale J Biol Med 1969;42:350-362.
43. Heiny A, Miotto O, Srinivasan KN, et al. Evolutionarily conserved protein sequences of influenza A viruses, avian and human, as vaccine targets. PLoS One 2007;2:1-14.
44. Hoffmann AA, Iturbe-Ormaetxe I, Callahan AG, et al. Stability of the wMel Wolbachia infection following invasion into the Aedes aegypti populations. PLoS Negl Trop Dis 2014;8:e3115.
45. Hoffmann AA, Montgomery BL, Popovichi J, et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 2011;476:454-457.
46. Holman DH, Wang D, Raviprakash K, et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol 2007;14:182-189.
47. Imrie A, Meeks J, Gurary A, et al. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol 2007;20:672-675.
48. Iturbe-Ormaetxe I, Walker T, and O'Neill SL. Wolbachia and biological control of mosquito-borne disease. EMBO Rep 2011;12:508-518.
49. Janice H, Akerstrom S, Shen S, et al. An antibody against a novel and conserved epitope in haemagglutinin 1 subunit neutralises numerous H5N1 influenza viruses. J Virol 2010;84:8275-8286.
50. Jechlinger W. Optimisation and delivery of plasmid DNA for vaccination. Exp Rev Vaccines 2006;5:803-825.
51. Kanesa-thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001;19:3179-3188.
52. Khali SM, Tonkin DR, Mattocks MD, et al. A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model. Vaccine 2014;32:4068-4074.
53. Konishi E, and Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 2002;20:1058-1067.
54. Krishnadas DK, Ahn JS, Han J, et al. Immunomodulation by hepatitis c virus-derived proteins: targeting human dendritic cells by multiple mechanisms. Int Immunol 2010;22:491-502.
55. Kuwahara M, and Konishi E. Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clin Vaccine Immunol 2010;17:1560-1566.
56. Leo YS, Wilder-Smith A, Archuleta D, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 years Phase II randomised controlled trial in Singapore. Hum Vaccin Immunother 2012;8:1259-1271.
57. Lin CF, Wan SW, Cheng HJ, et al. Autoimmune pathogenesis in dengue virus infection. Viral Immunol 2006;19: 127-132.
58. Lipstitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilius influenza and prospects for Streptococcous pneumonia. Emerg Infect Dis 1999;5:336-345.
59. Lipstitch M. Vaccination against colonising bacteria with multiple serotypes. Proc Natl Acad Sci U S A 1997;94:6571-6576.
60. Luplerdlop N, Misse D, Bray D, et al. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep 2006;7:1176-1181.
61. + T cells to heterologous serotypes. J Immunol 2005;175:2676-2683.
62. Mani S, Tripathi L, Raut R, et al. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titre neutralising antibodies. PLoS One 2013;8:1-9.
63. Mathew A, West K, Kalayanarooj S, et al. B-cell responses during primary and secondary infections in humans. J Infect Dis 2005;204:1514-1522.
64. Men R, Bray M, Clark D, et al. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996;70:3930-3937.
65. Men R, Wyatt L, Tokimatsu I, et al. Immunisation of rhesus monkeys with a recombinant of modified vaccina virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000;18:3113-3122.
66. Modis Y, Ogata S, Clements D, et al. A ligand binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 2003;100:6986-6991.
67. Modis Y, Ogata S, Clements D, et al. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 2005;79:1223-1231.
68. Morrison D, Legg TL, Billings CW, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in Flavivirus-naïve adults. J Infect Dis 2009;201:370-377.
69. Morrison J, Aguirre S, and Fernandez-Sesma A. Innate immunity evasion by dengue virus. Viruses 2012;4:397-413.
70. Murphy BR, and Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011;29:587-619.
71. Nam VS, Yen NT, Kay BH, et al. Eradication of Aedes aegytpi from a village in Vietnam, using copepods and community participation. Am J Trop Med Hyg 1998;59:657-660.
72. Nisalak A, Endy TP, Nimmannitya S, et al. Serotypespecific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973-1999. Am J Trop Med Hyg 2003;68:191-202.
73. Pierson TC, and Diamond MS. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2009;10:1-17.
74. Ramakrishnan L. "Novel vaccine candidate that offers protection over all four dengue serotypes", (Master of Science thesis, Manipal University, Manipal, Karnataka, India, 2013).
75. Ramanathan MP, Kuo Y, Selling BH, et al. Development of a novel DNA SynCon™ tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine 2009;29:6444-6447.
76. Rantam FA, Purwati, Soegijanto S, et al. Analysis of recombinant, multivalent dengue virus containing envelope (E) proteins from serotypes - 1, - 3, and - 4 and expressed in baculovirus. Trials Vaccinol 2013; doi: 10.1016/j.trivac.2013.10.001.
77. Raviprakash K, Wang D, Ewing D, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008;82:6927-6934.
78. Rothman AL, Kanesa-thasan N, West K, et al. Induction of T-lymphocyte responses to dengue virus by a candidate tetravalent live attenuated virus vaccine. Vaccine 2001; 19:4694-4699.
79. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature Rev Immunol 2011;11:532-543.
80. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002;66:264-272.
81. Sabchareon A. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012;380:1559-1567.
82. Seng CM, Setha T, Nealon J, et al. Community-based use of the larvivous fish Poecilia reticulata to control dengue vector Aedes aegypti in domestic water storage containers in rural Cambodia. J Vector Ecol 2008;33:139-144.
83. Shedlock DJ, Whitmire JK, Tan J, et al. Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J Immunol 2003;170:2053-2063.
84. Soundravally S, and Hoti SL. Significance of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in susceptibility to dengue viral infection. J Clin Immunol 2008;28:256-262.
85. Stanekova Z, and Vareckova E. Conserved epitopes of influenza a virus including protective immunity and their prospects for universal vaccine development. Virol J 2010; 7:1-13.
86. Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003;69:24-31.
87. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2004;197:823-829.
88. Tsai Y, Chang S, Lee C, et al. Human TLR3 recognises dengue virus and modulates viral replication in vitro. Cell Microbiol 2009;11:604-615.
89. Walker T, Johnson PH, Moreira LA, et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegpti. Nature 2011;476:450-453.
90. Watterson D, Kobe B, and Young PR. Residues in domain III of dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. J Gen Virol 2012; 93:73-83.
91. White LJ, Parsons MM, Whitmore AC, et al. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weaning mice. J Virol 2007;81:10329-10339.
92. White LJ, Sariol CA, Mattocks MD, et al. An alphavirus based-vector tetravalent dengue virus vaccine induces a rapid protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J Virol 2013;87:3409-3424.
93. Whitehead SS, Falgout B, Hanley KA, et al. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003; 77:1653-1657.
94. World Health Organization. Dengue Guidelines for Diagnosis, Treatment, Prevention, and Control 2009. Available at www.who.int/rpc/guidelines/9789241547871/en/ (accessed April 15, 2013).
95. World Health Organization. Global Strategy for Dengue Prevention and Control 2012-2020. Available at www.who.int/denguecontrol/control-strategies/en/ (accessed October 1, 2014).
96. Wu SF, Liao CL, Lin YL, et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 2003;21:3919-3929.
97. Yauch LE, Zellweger RM, Kotturi MF, et al. A protective role for dengue virus specific CD8+ T cells. J Immunol 2009;182:4865-4873.
98. Ye YH, Woolfit M, Rances E, et al. Wolbachia-associated bacterial protection in the mosquito Aedes aegypti. PLoS Negl Trop Dis 2013;7:e2362.
99. Zybert IA, van der Ende-Metselaar H, Wilschut J, et al. Functional importance of dengue virus maturation: infectious properties of immature virions. J Gen Virol 2008; 89:3047-3051.